NICE turns down Bayer's Xofigo
This article was originally published in Scrip
Executive Summary
NICE has rejected Bayer's prostate cancer drug Xofigo (radium-223 dichloride) because the company did not provide an "appropriate comparison" for NICE to assess cost-effectiveness.